Is it legal to use peptides in California?
It depends on which peptide you mean and where it comes from. “Peptides” covers FDA-approved medicines, pharmacy-compounded medicines and research chemicals sold online, and each sits in a different legal place. Here is where the main ones stand as of October 2026:
| Route | Examples | Status for a man in California |
|---|---|---|
| FDA-approved medicine | Tesamorelin (Egrifta) | Legal with a licensed clinician’s order; use for body composition is off-label |
| Compounded by a licensed pharmacy for one patient | Sermorelin | Legal with a licensed clinician’s order |
| Awaiting an FDA decision | BPC-157, TB-500, GHK-Cu | Unsettled; no final rule, so availability is uncertain |
| Not eligible for compounding | CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, Selank | Not available through compounding; not offered at Ultimate Male |
| Research chemicals | Vials labeled “not for human use” | Sold outside the drug system; not a medicine |
Tesamorelin’s FDA label covers reducing excess abdominal fat in adults with HIV-associated lipodystrophy, so any other use is off-label. It is also regulated as a biologic, which means it cannot be compounded at all.
Which federal rules decide whether a peptide can be compounded?
Federal law decides which ingredients a pharmacy may compound with. Under section 503A, the FDA says a pharmacy may only use bulk drug substances that meet one of three conditions:
- they comply with a USP or National Formulary monograph, if one exists;
- they are components of an FDA-approved drug, if no monograph exists; or
- they appear on the FDA’s 503A bulks list.
The ingredient must also come from an FDA-registered manufacturer with a valid certificate of analysis. Larger protein-based molecules, generally those over 40 amino acids, are regulated as biologics and fall outside this pathway, which is why tesamorelin and HCG (Pregnyl) cannot be compounded. Our answer on how compounding pharmacies make peptides walks through the process.
What changed for BPC-157, TB-500 and GHK-Cu in 2026?
Two steps happened, and neither finished the process. In April 2026, the FDA moved BPC-157, TB-500 and GHK-Cu off its list of substances that may present significant safety risks after their nominations were withdrawn. The page still records the FDA’s earlier concerns, including possible immune reactions and peptide-related impurities.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding BPC-157 and TB-500 to the 503A bulks list, against the advice of FDA staff. A committee vote is a recommendation, and no final rule has followed. GHK-Cu is due for the same kind of review by early 2027.
The key point for patients is that leaving the safety-concern list does not, on its own, make a substance eligible for compounding. Our article on the FDA’s 2026 peptide decisions covers each step in detail.
What does California law add?
California layers its own pharmacy rules on top of federal law, and they matter most for injectables. According to the California Board of Pharmacy’s 2026 Lawbook for Pharmacy:
- a pharmacy may not compound sterile drug products without a sterile compounding license from the board, and the location must be inspected before the license is issued or renewed (Business and Professions Code section 4127.1);
- an out-of-state pharmacy may not compound sterile products for shipment into California without its own sterile compounding license from the board (section 4127.2);
- ingredients labeled “not for human use,” “not for injectable use” or similar may not be used to make sterile compounded preparations (California Code of Regulations, title 16, section 1736.9).
You can check any pharmacy’s California license with the state’s Department of Consumer Affairs license search. A seller that does not appear there is not a California-licensed pharmacy. For a look at how research-labeled products compare, see our answer on whether research peptides are safe to inject.
Are legal peptides allowed in tested sports?
Not necessarily, and the answer is separate from pharmacy law. BPC-157 and TB-500 are on the World Anti-Doping Agency’s prohibited list regardless of their compounding status, and other peptides may be covered too, so check the list before you start. Our answer on peptides banned for tested athletes covers which ones and why.
How Ultimate Male decides which peptides to offer
Our peptide therapy program at San Gabriel and Downey only uses peptides that can be supplied lawfully: the FDA-approved product where one exists, such as tesamorelin, or a medicine prepared by a licensed U.S. compounding pharmacy, such as sermorelin. Every plan starts with labs and a one-on-one consultation, and a consultation is an evaluation, not a promise of treatment.
For BPC-157, TB-500 and GHK-Cu, we will tell you on the free 10-minute call exactly where supply stands on the day you ask. If you are also curious about other hormones and California rules, our answer on whether TRT is legal in California covers testosterone.
